Developing new antifungal drugs in a specialized lab
BSL3 Drug Screening Core
This study is working on a special lab to quickly test many new medicines to find out which ones can help fight harmful fungi that cause infections, with the hope that patients will have better treatment options in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11004651 on NIH RePORTER |
What this research studies
This research focuses on creating a high-throughput screening (HTS) facility that operates under strict biosafety level 3 (BSL-3) conditions to test thousands of compounds for their effectiveness against harmful fungi, specifically Coccidioides spp. The goal is to establish methods for quickly and efficiently identifying new antifungal agents that can combat these pathogens. By using advanced techniques like imaging flow cytometry, the research aims to understand how these new drugs work and their potential effectiveness. Patients may benefit from new treatment options that arise from this innovative drug discovery process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by Coccidioides spp. or other severe fungal infections.
Not a fit: Patients with non-fungal infections or those who do not have a history of severe fungal infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal medications that are more effective against serious fungal infections.
How similar studies have performed: Other research has successfully utilized high-throughput screening in similar contexts, indicating a promising approach for drug discovery in this area.
Where this research is happening
San Antonio, United States
- University of Texas San Antonio — San Antonio, United States (Active)
Researchers
- Principal investigator: Lopez-Ribot, Jose L. — University of Texas San Antonio
- Study coordinator: Lopez-Ribot, Jose L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.